Gedatolisib plus fulvestrant and palbociclib (the “gedatolisib-triplet”) reduced the risk of disease progression or death by 50% vs. alpelisib ...

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: ...

An intravenous (i.v.) formulation of fulvestrant was developed for use in pharmacokinetic investigations since plasma concentrations of fulvestrant administered by the i.m. route are determined by the ...

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive, human ...

Novel gedatolisib is currently under review at FDA for wild-type patients ...

Review the side-effects of Fulvestrant as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The appraisal committee (section 4) considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of fulvestrant, having considered evidence on the nature of locally advanced or metastatic breast cancer and ...

Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer Patients were randomly assigned at a ...

A new investigational drug called gedatolisib can help keep cancer from returning for longer for certain patients with HR+, ...

The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more ...